Jed Bayasi, MD
Pulmonary Disease · Gilbert, AZNPI 1538207238
Payments from drug & device makers
Across 246 payments — averaging $34.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$4K
- AstraZeneca$715
- Philips North America LLC$558
- Boehringer Ingelheim$388
- Insmed, Inc.$347
- GSK$321
- plus $2K from 23 others
What the payments were for
- Consulting fees$4,30050%
- Food & beverage$4,17649%
- Education$1131%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 8 | $4,373 |
| AstraZeneca | 37 | $715 |
| Philips North America LLC | 37 | $558 |
| Boehringer Ingelheim | 29 | $388 |
| Insmed, Inc. | 22 | $347 |
| GSK | 27 | $321 |
| Grifols USA, LLC | 20 | $318 |
| Mylan Specialty L.p. | 11 | $242 |
| Genentech USA, Inc. | 6 | $202 |
| Inari Medical, Inc. | 1 | $144 |
| Advanced Respiratory, Inc | 8 | $111 |
| Actelion Pharmaceuticals US, Inc. | 5 | $104 |
| Mallinckrodt Hospital Products Inc. | 3 | $93 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $74 |
| Regeneron Healthcare Solutions, Inc. | 4 | $70 |
| Inspire Medical Systems, Inc. | 2 | $53 |
| Baxter Healthcare | 3 | $51 |
| Sanofi | 3 | $47 |
| ZOLL Respicardia, Inc. | 2 | $44 |
| Jazz Pharmaceuticals Inc. | 2 | $42 |
| Covis Pharma GmbH | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Pulmonx Corporation | 1 | $32 |
| United Therapeutics Corporation | 1 | $24 |
| Merck | 2 | $23 |
| Circassia Inc. | 1 | $20 |
| Viatris Specialty LLC | 1 | $18 |
| Electromed, Inc. | 2 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,588 in reported general payments places this provider in the 65th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 18 | $229,926 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 204 | $204,453 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 240 | $162,120 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 139 | $91,241 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 93 | $88,062 |
| OzempicSemaglutide | 76 | $83,046 |
| Spiriva HandihalerTiotropium Bromide | 52 | $41,014 |
| Breo ElliptaFluticasone/Vilanterol | 67 | $39,915 |
| Advair HfaFluticasone Propion/Salmeterol | 66 | $30,458 |
| MounjaroTirzepatide | 21 | $29,626 |
| SymbicortBudesonide/Formoterol Fumarate | 80 | $22,744 |
| Spiriva RespimatTiotropium Bromide | 33 | $19,222 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 36 | $15,850 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 467 | $9,509 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 54 | $8,871 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $388 | $411,267291 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $321 | $338,368423 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $715 | $126,656209 claims |
| Novo NordiskOzempic | $4,373 | $83,04676 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $38 | $3,82913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Gilbert
- Richard SueGilbert$624K
- Archan ShahGilbert$20K
- Harmeet GillGilbert$17K
- Amy BohanGilbert$17K
- Thomas SlobigGilbert$16K
- Wahaj AhmedGilbert$15K
- Muhammad SalimChandler$5.9M
- Vikas SayalBullhead City$3.7M
- David BaratzPhoenix$2.2M
- James RossPhoenix$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.